BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Core Insights - BioAtla, Inc. presented promising data on Mecbotamab Vedotin (Mec-V) for treatment-refractory non-small cell lung cancer (NSCLC) with mutated KRAS (mKRAS), showing a one-year overall survival (OS) of 58% compared to 23% for wild-type KRAS (wtKRAS) patients [1][3][4] Group 1: Clinical Trial Results - The Phase 2 trial of Mec-V included 78 patients, with 30.7% having mKRAS NSCLC [4] - Among patients with mKRAS NSCLC, the median OS was not yet reached, while the median OS for wtKRAS was 8.7 months [4] - The overall response rate (ORR) for mKRAS NSCLC patients was 28.6%, with notable antitumor activity across 9 different mKRAS variants [4] Group 2: Mechanism and Targeting - Mec-V is a conditionally active antibody-drug conjugate targeting AXL, which is highly expressed in mKRAS NSCLC [6][4] - A strong correlation was confirmed between mKRAS mutations and AXL expression, with 70.3% of NSCLC samples harboring KRAS mutations showing high AXL expression [3][4] Group 3: Future Plans - BioAtla plans to initiate a randomized trial of Mec-V in 2025 for patients with treatment-refractory mKRAS NSCLC based on the encouraging findings [3][4] - The company has received Orphan Drug Designation from the FDA for Mec-V in treating soft tissue sarcoma, indicating its potential across multiple solid tumor indications [6]